BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23480749)

  • 1. Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma.
    Jusakul A; Khuntikeo N; Haigh WG; Kuver R; Ioannou GN; Loilome W; Namwat N; Bhudhisawasdi V; Pugkhem A; Pairojkul C; Yongvanit P
    Asian Pac J Cancer Prev; 2012; 13 Suppl():77-82. PubMed ID: 23480749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.
    Zhang X; Yang Z; Shi Z; Zhu Z; Li C; Du Z; Zhang Y; Wang Z; Jiao Z; Tian X; Zhang J; Zhai W; Kan Q
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105775. PubMed ID: 33130021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum unconjugated primary and secondary bile acids in patients with cholangiocarcinoma and hepatocellular carcinoma.
    Changbumrung S; Tungtrongchitr R; Migasena P; Chamroenngan S
    J Med Assoc Thai; 1990 Feb; 73(2):81-90. PubMed ID: 2161896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice.
    Sombattheera S; Proungvitaya T; Limpaiboon T; Wongkham S; Wongkham C; Luvira V; Proungvitaya S
    Asian Pac J Cancer Prev; 2015; 16(4):1367-70. PubMed ID: 25743800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
    Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of bile and serum mucin5AC in cholangiocarcinoma: diagnostic performance and biologic significance.
    Danese E; Ruzzenente O; Ruzzenente A; Iacono C; Bertuzzo F; Gelati M; Conci S; Bendinelli S; Bonizzato G; Guglielmi A; Salvagno GL; Lippi G; Guidi GC
    Surgery; 2014 Nov; 156(5):1218-24. PubMed ID: 25151557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.
    Boyd S; Mustonen H; Tenca A; Jokelainen K; Arola J; Färkkilä MA
    Scand J Gastroenterol; 2017 Feb; 52(2):242-249. PubMed ID: 27806633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy.
    Sharif AW; Williams HR; Lampejo T; Khan SA; Bansi DS; Westaby D; Thillainayagam AV; Thomas HC; Cox IJ; Taylor-Robinson SD
    HPB (Oxford); 2010 Aug; 12(6):396-402. PubMed ID: 20662790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of biliary alkaline phosphatase in non-jaundiced cholangiocarcinoma.
    Bhudhisawasdi V; Muisuk K; Areejitranusorn P; Kularbkaew C; Khampitak T; Saeseow OT; Wongkham S
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):87-92. PubMed ID: 14648209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
    Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
    Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
    Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
    Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development.
    Lozano E; Sanchez-Vicente L; Monte MJ; Herraez E; Briz O; Banales JM; Marin JJ; Macias RI
    Mol Cancer Res; 2014 Jan; 12(1):91-100. PubMed ID: 24255171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions.
    Cossiga V; Guarino M; Capasso M; Morisco F
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Bile Acid Profiling and Modulation of Secreted Mucin 5AC in Cholangiocarcinoma.
    Danese E; Lievens PM; Padoan A; Peserico D; Galavotti R; Negrini D; Gelati M; Conci S; Ruzzenente A; Salvagno GL; Lippi G
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL; Fogt F; Burke M; Murakata LA
    Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current problems with intrahepatic bile duct stones in Japan--congenital biliary malformations as a cause.
    Fujii H; Yang Y; Matsumoto Y; Suda K
    Hepatogastroenterology; 1997; 44(14):328-41. PubMed ID: 9164499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.